Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get trading ideas, historical data, advanced options screeners, more. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Galmed Pharmaceutica (GLMD)

Galmed Pharmaceutica (GLMD)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,672
  • Shares Outstanding, K 25,088
  • Annual Sales, $ 0 K
  • Annual Income, $ -32,470 K
  • 60-Month Beta 1.44
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.48
Trade GLMD with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.90
  • Most Recent Earnings -0.21 on 11/16/22
  • Next Earnings Date 11/21/22
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 688.84% ( +688.84%)
  • Historical Volatility 67.96%
  • IV Percentile 93%
  • IV Rank 50.02%
  • IV High 1,355.81% on 07/08/22
  • IV Low 21.42% on 02/18/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 0
  • Volume Avg (30-Day) 1
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 98
  • Open Int (30-Day) 85

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -0.15
  • Number of Estimates 2
  • High Estimate -0.14
  • Low Estimate -0.15
  • Prior Year -0.30
  • Growth Rate Est. (year over year) +50.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2900 +5.45%
on 11/30/22
0.4100 -25.41%
on 11/10/22
-0.0942 (-23.55%)
since 11/02/22
3-Month
0.2900 +5.45%
on 11/30/22
0.4900 -37.59%
on 10/10/22
-0.1442 (-32.04%)
since 09/02/22
52-Week
0.2900 +5.45%
on 11/30/22
2.4987 -87.76%
on 12/08/21
-2.1242 (-87.42%)
since 12/02/21

Most Recent Stories

More News
Galmed Pharmaceuticals: Q3 Earnings Snapshot

Galmed Pharmaceuticals: Q3 Earnings Snapshot

GLMD : 0.3058 (+1.93%)
Galmed Pharmaceuticals (GLMD) Moves to Buy: Rationale Behind the Upgrade

Galmed Pharmaceuticals (GLMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

GLMD : 0.3058 (+1.93%)
Endo (ENDP) Inks Deal to Develop Rare Disease Drug in Canada

Endo's (ENDP) subsidiary, Endo Ventures, signs agreement with Quoin Pharmaceuticals for developing/commercializing the latter's pipeline candidate, QRX003, for treating Netherton syndrome in Canada.

ENDP : 0.2926 (-5.00%)
GLMD : 0.3058 (+1.93%)
VRCA : 3.36 (+5.66%)
QNRX : 1.7500 (+1.16%)
Aldeyra's (ALDX) Dry Eye Disease Chamber Study Meets Goals

Aldeyra's (ALDX) vehicle-controlled crossover study evaluating 0.25% reproxalap ophthalmic solution for the treatment of dry eye disease meets primary endpoints. Shares up.

SPPI : 0.4700 (-0.51%)
PTN : 4.01 (-3.37%)
GLMD : 0.3058 (+1.93%)
ALDX : 6.52 (+5.84%)
Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification

/PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic,...

GLMD : 0.3058 (+1.93%)
Evotec (EVO) Inks Drug Discovery Collaboration Deal With J&J

Evotec (EVO) signs a collaboration agreement with Janssen, a wholly owned subsidiary of J&J, for discovering novel drugs in the field of protein homeostasis. Shares down.

JNJ : 178.88 (+0.08%)
GLMD : 0.3058 (+1.93%)
EVO : 9.14 (-0.54%)
EXAI : 6.14 (+6.41%)
1 Biotech Stock to Buy and 1 to Sell

Increasing investments in R&D to develop new therapies, rising cases of chronic diseases, and an aging population should drive the biotech market’s growth. Therefore, we think it could be wise to invest...

GLMD : 0.3058 (+1.93%)
VRTX : 321.37 (+0.19%)
Galmed Pharmaceuticals: Q3 Earnings Snapshot

TEL AVIV, Israel (AP) _ Galmed Pharmaceuticals Ltd. (GLMD) on Monday reported a loss of $7.7 million in its third quarter.

GLMD : 0.3058 (+1.93%)
CTI BioPharma (CTIC) Dips on Top-Line Data from COVID-19 Study

CTI BioPharma (CTIC) posts top-line data from the PRE-VENT study evaluating pacritinib/standard of care as a treatment of severe COVID-19 infection.

CTIC : 5.99 (+0.17%)
INFI : 0.5489 (+1.65%)
GLMD : 0.3058 (+1.93%)
ATXI : 1.4800 (+4.23%)
Pacira (PCRX) Gets Notification of ANDA for Exparel, Stock Down

Pacira (PCRX) receives a Paragraph IV Certification notice letter notifying that eVenus has submitted an ANDA for marketing a generic version of Exparel in the United States.

INFI : 0.5489 (+1.65%)
PCRX : 47.25 (+0.04%)
GLMD : 0.3058 (+1.93%)
ATXI : 1.4800 (+4.23%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. It is focused on developing therapies for liver diseases and gallstones. Galmed Pharmaceuticals Ltd. is based in Tel Aviv, Israel.

See More

Key Turning Points

3rd Resistance Point 0.3352
2nd Resistance Point 0.3269
1st Resistance Point 0.3164
Last Price 0.3058
1st Support Level 0.2976
2nd Support Level 0.2893
3rd Support Level 0.2788

See More

52-Week High 2.4987
Fibonacci 61.8% 1.6550
Fibonacci 50% 1.3943
Fibonacci 38.2% 1.1337
Last Price 0.3058
52-Week Low 0.2900

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar